1. 1US Renal Data System: USRDS 2006 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2006;.
2. 2Foley R, Parfrey P, Sarnak M. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(suppl 12):S16–S23. MEDLINE
3. 3Kim BS, Jeon DS, Shin MJ, et al. Persistant elevation of C-reactive protein may predict cardiac hypertrophy and dysfunction in patients maintained on hemodialysis. Am J Nephrol. 2005;25:189–195. MEDLINE |
CrossRef
4. 4Goodman WG. Vascular calcification in end-stage renal disease. J Nephrol. 2002;15(suppl 6):S82–S85.
5. 5Brasier AR, Recinos A, Eledrisi MS. Vascular inflammation and rennin-angiotensin system. Atheroscler Thromb Vasc Biol. 2002;22:1257–1266.
6. 6Foley RN, Parfrey PS, Harnett JD, et al. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28:53–61. Abstract |
Full-Text PDF (911 KB)
|
CrossRef
7. 7Goicoechea M, Martin J, de Sequera P, et al. Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int. 1998;54:1337–1343. MEDLINE |
CrossRef
8. 8Stenvinkel P, Lindholm B, Heimburger O. Novel approaches on an integrated therapy of inflammatory-associated wasting in end-stage renal disease. Semin Dialysis. 2004;17:505–515.
9. 9Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019.
CrossRef
10. 10Stedman TL. In: Stedman’s Medical Dictionary. (ed 26). Baltimore, MD: Williams and Wilkins; 1995;p. 869.
11. 11Pecoits-Filho R, Heimburger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis. 2003;41:1212–1218. Abstract | Full Text |
Full-Text PDF (72 KB)
12. 12Urieli-Shoval S, Linke R, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000;7:64–69. MEDLINE |
CrossRef
13. 13Bathon J, Graves J, Jens P, et al. The erythrocyte sedimentation rate in end-stage renal failure. Am J Kidney Dis. 1987;10:34–40. Abstract
14. 14Ortega O, Rodriguez I, Gallar P, et al. Significance of high C-reactive protein levels in pre-dialysis patients. Nephrol Dial Transplant. 2002;17:1105–1109. MEDLINE |
CrossRef
15. 15Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–658. MEDLINE |
CrossRef
16. 16Yeun JY, Levine RA, Mantadilok V, et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–476. Abstract | Full Text |
Full-Text PDF (60 KB)
|
CrossRef
17. 17Memoli B, Libetta C, Rampino T, et al. Hemodialysis-related induction of interleukin-6 production by peripheral blood mononuclear cells. Kindey Int. 1992;42:320–326.
18. 18Liu Y, Berthier-Schaad Y, Fallin MD, et al. IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol. 2006;17:863–870. MEDLINE |
CrossRef
19. 19Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87–92.
CrossRef
20. 20Pecoits-Filho R, Barany P, Lindholm B, et al. Interleukin-6 is an independent predictor in mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002;17:1684–1688. MEDLINE |
CrossRef
21. 21Conti G, Amore A, Chiesa M, et al. Procalcitonin as a marker of micro-inflammation in hemodialysis. J Nephrol. 2005;18:282–288. MEDLINE
22. 22Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia—The good, the bad, and the ugly. Kidney Int. 2005;67:1216–1233. MEDLINE |
CrossRef
23. 23Pereira BJ, Shapiro L, King AJ, et al. Plasma levels of IL-1 beta, TNF-alpha and their specific inhibitors in undialyzed chronic renal failure, CAPD, and hemodialysis patients. Kidney Int. 1994;45:890–896. MEDLINE |
CrossRef
24. 24Seyrek N, Karayaylali I, Balal M, et al. Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients?. Scand J Urol Nephrol. 2005;39:405–409. MEDLINE |
CrossRef
25. 25Kalousova M, Zima T, Tesar V. Carbonyl stress and chronic renal failure. Casopis Lekaru Ceskych. 2002;141:143–145.
26. 26Miyata T, Oda O, Inagi R, et al. Beta 2-microglobulin modified with advanced glycation end product is a major component of hemodialysis-associated amyloidosis. J Clin Invest. 1993;92:1243–1252. MEDLINE |
CrossRef
27. 27Morena M, Dilbosc S, Dupuy A, et al. Overproduction of reactive oxygen species in end-stage renal disease patients: A potential component of hemodialysis associated inflammation. Hemodialysis Int. 2005;9:37–46.
28. 28Sela S, Shurtz-Swirski R, Cohen-Mazor M, et al. Primed peripheral polymorphonuclear leukocyte: A culprit underlying chronic low-grade inflammation and systemic oxidative stress in chronic kidney disease. J Am Soc Nephrol. 2005;16:2431–2438. MEDLINE |
CrossRef
29. 29Babior BM. NADPH oxidase: An update. Blood. 1999;93:1464–1476. MEDLINE
30. 30Brennan ML, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol. 2003;14:353–359. MEDLINE |
CrossRef
31. 31Miyata T, Ueda Y, Horie K, et al. Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int. 1998;53:416–422. MEDLINE |
CrossRef
32. 32Sharma R, Bolger AP, Li W, et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol. 2003;92:188–193. Abstract | Full Text |
Full-Text PDF (207 KB)
|
CrossRef
33. 33Kjellstrand CM, Evans RL, Peterson RJ, et al. The “unphysiology” of dialysis: A major cause of dialysis side effects?. Kidney Int. 1975;7:S30–S34.
34. 34Lindsay RM, Leitch R, Heidenheim A, et al. The London Daily/Nocturnal Hemodialysis Study—Study design,morbidity, and mortality results. Am J Kidney Dis. 2003;42(suppl 1):5–12. Abstract | Full Text |
Full-Text PDF (68 KB)
35. 35Woods JD, Port FK, Orzol S, et al. Clinical and biochemical correlates of starting “daily” hemodialysis. Kidney Int. 1999;55:2467–2476. MEDLINE |
CrossRef
36. 36Nesrallah G, Suri R, Moist L, et al. Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis. 2003;42:13–17. Abstract | Full Text |
Full-Text PDF (76 KB)
37. 37Fagugli RM, Reboldi G, Quintaliani G. Short daily dialysis: Blood pressure control and left ventricular mass reduction in hypertensive patients. Am J Kidney Dis. 2001;38:371–376. Abstract |
Full-Text PDF (47 KB)
|
CrossRef
38. 38Mahmud A, Freely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension. 2005;46:1118–1122.
CrossRef
39. 39Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective controlled study. J Am Soc Nephrol. 2005;16:2778–2788. MEDLINE |
CrossRef
40. 40Chan CT, Floras JS, Miller JA, et al. Improvement in ejection fraction by nocturnal hemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant. 2002;17:1518–1521. MEDLINE |
CrossRef
41. 41Torun D, Sezer S, Baltali M, et al. Association of cardiac valve calcification and inflammation in patients on hemodialysis. Ren Fail. 2005;27:221–226.
CrossRef
42. 42Chan CT, Li SH, Verma S. Nocturnal hemodialysis is associated with restoration of impaired endothelial progenitor cell biology in end-stage renal disease. Am J Physiol Renal Physiol. 2005;289:F679–F684. MEDLINE |
CrossRef
43. 43Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004;109:2058–2067.
CrossRef
44. 44Jofre R, Rodriguez-Benitez P, Lopez-Gomez J, et al. Inflammatory syndrome in patients on hemodialysis. J Am Soc Nephrol. 2006;17:274–280.
45. 45Nadra I, Mason J, Phillippides P, et al. Proinflammatory activation of macrophages by basic calcium phosphate crystal via protein kinase C and MAP kinase pathways (A vicious cycle of inflammation and arterial calcification). Circ Res. 2005;96:1248–1256.
CrossRef
46. 46Chan CT, Mardirossian S, Faratro R, et al. Improvement of lower-extremity peripheral arterial disease by nocturnal hemodialysis. Am J Kidney Dis. 2003;41:225–229. Abstract |
Full-Text PDF (169 KB)
|
CrossRef
47. 47Kaysen G, Elserich JP. Characteristics and effects of inflammation in end-stage renal disease. Semin Dial. 2003;16:438–446. MEDLINE |
CrossRef
48. 48Bugeja AL, Chan CT. Improvement in lipid profile by nocturnal hemodialysis in patients with end-stage renal disease. Trans Am Soc Artif Intern Organs. 2004;50:328–331.
49. 49Trey JE, Kushner I. The acute phase response and the hemotopoietic system (The role of cytokines). Crit Rev Oncol Hematol. 1995;21:1–18.
Full-Text PDF (2379 KB)
|
CrossRef
50. 50Yuen D, Richardson R, Fenton S, et al. Quotidian nocturnal hemodialysis improves cytokine profile and enhances erythropoietin responsiveness. Trans Am Soc Artif Intern Organs. 2005;51:236–241.
51. 51Schwartz DI, Pierratos A, Richardson RM, et al. Impact of nocturnal hemodialysis on anemia management in patients with end-stage renal disease. Clin Nephrol. 2005;63:202–208. MEDLINE
52. 52Beddhu S, Kaysen GA, Yan G, et al.HEMO Study Group Association of serum albumin and atherosclerosis in chronic hemodialysis patients. Am J Kidney Dis. 2002;40:721–727. Abstract | Full Text |
Full-Text PDF (54 KB)
|
CrossRef
53. 53Beddhu S, Pappas LM, Ramkumar N, et al. Malnutrition and atherosclerosis in dialysis patients. J Am Soc Nephrol. 2004;15:733–742. MEDLINE |
CrossRef
54. 54Eustace JA, Astor B, Muntner PM, et al. Prevalence of acidosis and inflammation and their association with low serum albumin in chronic kidney disease. Kidney Int. 2004;65:1031–1040. MEDLINE |
CrossRef
55. 55Suliman ME, Heimburger O, Barany P, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003;14:1614–1622. MEDLINE |
CrossRef
56. 56Fagugli RM, Vanholder R, De Smet R, et al. Advanced glycation end products: Specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis. Int J Artif Organs. 2001;24:256–262. MEDLINE
57. 57Ikizler TA, Flakoll PJ, Parker RA, et al. Amino acid and albumin losses during hemodialysis. Kidney Int. 1994;46:830–837. MEDLINE |
CrossRef
58. 58Pierratos A. Nocturnal home hemodialysis: An update on a 5-year experience. Nephrol Dial Transplant. 1999;14:2835–2840. MEDLINE |
CrossRef
59. 59Galland R, Traeger J, Arkouche W, et al. Short daily hemodialysis rapidly improves nutritional status in hemodialysis patients. Kidney Int. 2001;60:1555–1560. MEDLINE |
CrossRef
60. 60Wiggins KJ, Somerville CA, Knight R, et al. Intradialytic protein concentrations differ between nightly nocturnal and conventional hemodialysis. Nephrology. 2005;10:325–329. MEDLINE |
CrossRef
61. 61Spanner E, Suri R, Heidenheim AP, et al. The impact of quotidian hemodialysis on nutrition. Am J Kidney Dis. 2003;42(suppl 1):30–35. Abstract | Full Text |
Full-Text PDF (45 KB)
62. 62Lindsay RM, Nesrallah G, Suri R, et al. Is more frequent hemodialysis beneficial and what is the evidence?. Curr Opin Nephrol Hypertens. 2004;13:631–635. MEDLINE |
CrossRef
63. 63Nokher W, Scherberich J. Monocyte cell-surface CD14 expression and soluble CD14 antigen in hemodialysis: Evidence for chronic exposure to LPS. Kidney Int. 1995;48:1469–1476. MEDLINE |
CrossRef
64. 64Griveas I, Visvardis G, Sakellariou G, et al. Biocompatibility study based on differential sequestration kinetics of CD14+CD16+ blood monocyte subsets with different dialyzers. Ren Fail. 2006;28:493–499.
CrossRef
65. 65Korevaar JC, van Manen JG, Dekker FW, et al.NECOSAD Study Group Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol. 2004;15:2916–2922. MEDLINE |
CrossRef
66. 66Azevedo SM, Carmichael WW, Jochimsen EM, et al. Human intoxication by microcystins during renal dialysis treatment in Caruaru-Brazil. Toxicology. 2002;181:441–446.
CrossRef
67. 67Hoenich NA, Levin R. The implication of water quality in hemodialysis. Semin Dial. 2003;16:492–497. MEDLINE |
CrossRef
68. 68Schiffl H, Lang SM, Stratakis D, et al. Effect of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant. 2001;16:1863–1869. MEDLINE |
CrossRef
69. 69Ward RA. Ultrapure dialysate. Semin Dial. 2004;17:489–497. MEDLINE |
CrossRef
70. 70Lederer SR, Schiffl H. Ultrapure dialysis fluid lowers the cardiovascular morbidity in patients on maintenance hemodialysis by continuous microinflammation. Nephron. 2002;91:452–455.
71. 71Lamas JM, Alonso M, Sastre F, et al. Ultrapure dialysate and inflammatory response in hemodialysis evaluated by darbepoetin requirements—A randomized study. Nephrol Dial Transplant. 2006;21:2851–2858. MEDLINE |
CrossRef
72. 72Amore A, Cirina P, Bonaudo R, et al. Bicarbonate dialysis, unlike acetate-free biofiltration, triggers mediators of inflammation and apoptosis in endothelial and smooth muscle cells. J Nephrol. 2006;19:57–64. MEDLINE
73. 73Kaysen GA. The microinflammatory state in uremia and causes and potential consequences. J Am Soc Nephrol. 2001;12:1549–1557. MEDLINE
74. 74Piccoli GB, Bermond F, Mezza E, et al. Vascular access survival and morbidity on daily dialysis: A comparative analysis of home and limited care hemodialysis. Nephrol Dial Transplant. 2004;19:2084–2094. MEDLINE |
CrossRef